Encapsulation Technology — Supplier Qualification Guide

Key Technical Parameters #

Encapsulated actives fail in finished products for one reason more than any other: the raw material never met spec to begin with. Brand partners brief us on retinol 0.3%, peptide complexes, vitamin C derivatives — and the first thing we do before any lab work is run our incoming material through what we internally call the MTL-IQ (Material Qualification Log) gate. If the encapsulated raw material doesn’t pass that gate, nothing downstream matters. This guide covers exactly what COA fields we require, the pass/fail thresholds we apply, and the supplier behaviours that make us stop the process entirely. It’s most relevant for brands working with functional actives in serum, moisturiser, or targeted treatment formats where encapsulation is doing real performance work, not just label decoration.

COA Field Requirements and What the Numbers Actually Tell You #

A COA for an encapsulated active is not the same as a COA for a bulk powder. We see this confusion constantly. Suppliers sometimes submit a COA that lists assay of the active ingredient and nothing else — no particle size, no encapsulation efficiency, no shell material purity. That document is functionally useless for qualifying encapsulated material.

Here’s what we require on every incoming COA for an encapsulated active, alongside the thresholds we apply during incoming inspection:

A few notes on how we interpret this table in practice. EE% below 85% doesn’t automatically mean rejection — it means we run an additional free-active stability assay before making a call. For polymer microsphere materials (PLGA-based), we accept slightly wider PDI ranges, up to 0.35, because the manufacturing process is less controlled than lipid-based systems. We document all exceptions under our MTL-IQ exception log before the batch proceeds.

Zeta potential is the number suppliers most frequently argue with us about. We’ve had suppliers claim zeta potential is “not relevant” for their system. Our position: if you can’t measure it, you don’t understand your product’s stability mechanism, and we won’t qualify you.

The encapsulation efficiency method also matters — and this is where COA fraud is most likely. EE% can be calculated by difference (total active minus free active) or by direct measurement of free active via HPLC after membrane separation. The difference method systematically over-reports EE% if there’s any loss during processing. We require the HPLC method. Any supplier that can’t specify which method they used on the COA is flagged immediately.

Our encapsulation technology work spans lipid, polymer, and cyclodextrin systems, and the incoming qualification burden is different across each — but the COA completeness requirement is non-negotiable across all of them.

Root Cause Analysis — Why Encapsulated Actives Fail After Incoming Approval #

This is the section that matters most, so we’re going to spend time here.

Scenario 1: Shell Oxidation Masked at Incoming

Lipid-based encapsulates — liposomes, NLC, SLN — use phospholipid or triglyceride shells that oxidise over time. A supplier ships material at peroxide value 4.2 meq/kg, which passes our ≤5 threshold. But the material was manufactured 11 months ago and has been sitting in a warehouse in a non-inert atmosphere. By the time we compound at scale, the shell has degraded further. By week 8 of accelerated stability (40°C/75% RH), retinol assay drops from 0.29% to 0.17% in the finished formula — well below the 0.3% target.

What to check: Always request manufacture date, not just expiry date. Calculate shelf-life consumed. If a supplier cannot provide the manufacture date, that’s a disqualifying condition in our process. We also request nitrogen-blanketed storage certification for lipid-based materials as standard.

Scenario 2: Particle Size Passes D50, Fails on Application

D50 of 180 nm passes spec. D90 of 620 nm does not — and we missed it because the supplier reported only D50 on the COA. The finished serum had visible gritty texture at 5% loading. Consumers described it as “rough.” The issue wasn’t the formulation. The issue was a tail population of oversized particles that wasn’t visible in the D50 figure.

We now require D10, D50, and D90 on all incoming particle size reports. For nano-range materials, we run our own DLS check on every lot regardless of supplier data — not because we distrust all suppliers, but because particle size distribution is the single parameter most commonly misreported, intentionally or otherwise.

Scenario 3: PDI Creep Across Lots

This one is subtle and takes time to catch. A supplier qualifies with PDI 0.18 on three initial lots. Lots 4 through 7 come in at 0.21, 0.23, 0.26, 0.29. Each lot passes the ≤0.25 threshold individually — except lot 7. But the trend tells you the manufacturing process is drifting. By the time you catch lot 7, you’ve already used lots 4, 5, and 6 in production. We track PDI trending across supplier lots using a simple control chart approach, flagged in our supplier scorecard at the six-month review. If three consecutive lots show upward PDI drift of more than 0.03 per lot, we issue a supplier corrective action request before hitting the threshold breach.

Honestly, most of the supplier issues we catch are trend issues, not single-lot failures. Single-lot testing is table stakes. Trend monitoring is where you actually protect your formulations.

Scenario 4: The Microbial Problem Nobody Talks About

Oil-rich encapsulated materials — especially those with plant-derived emollient shells — can support microbial growth in ways that standard anhydrous raw materials don’t. We had one incoming lot of a botanical extract encapsulate (shea-derived lipid shell, phytosterol complex inside) that passed TPC at 80 CFU/g. Within six weeks of opening, the same lot tested at 1,400 CFU/g. The packaging was not hermetically sealed, and the material had been partially used from a 20kg drum over multiple production runs.

This goes beyond supplier qualification into handling protocol, but the root cause was a supplier who specified single-use packaging as a recommendation rather than a requirement. We now require tamper-evident, nitrogen-purged packaging for all lipid-based encapsulates with water activity above 0.3, and we specify this as a purchase order condition, not a preference.

Does Supplier Certification Replace Incoming Inspection? #

Short answer: no, and we’d push back hard on any brand that tried to skip incoming testing on the basis of a supplier’s ISO 9001 or GMP certificate.

Certification tells you a supplier has a quality system. It does not tell you that any given lot meets spec. The ISO Standards framework for cosmetic ingredient quality management is process-oriented, not outcome-oriented. A certified supplier can still ship a bad lot. We’ve seen it. What certification does is reduce the frequency of bad lots and give you a formal corrective action mechanism when they occur — that’s the actual value.

Under EU Cosmetics Regulation 1223/2009, the finished product manufacturer (in most OEM arrangements, that’s us) bears responsibility for the safety and conformity of the final product. Supplier certification does not transfer that liability. If an encapsulated retinol serum causes an adverse event linked to excess free retinol from inadequate encapsulation, the COA from the supplier is not a legal defence. This shapes how we approach our incoming protocol — not as a courtesy check, but as a manufacturing control.

For brands selling in the US market, FDA Cosmetics Guidelines are less prescriptive on incoming raw material testing, but the liability logic is identical. The finished product manufacturer is accountable.

Red Flags in Supplier Behaviour — What Triggers Disqualification #

There are COA-level red flags and then there are interaction-level red flags. Both matter.

On the COA side: round numbers are suspicious. An EE% reported as exactly 90.0% across four consecutive lots is statistically improbable if the measurement method has any real variability. Legitimate analytical data has decimal scatter. When every lot comes back at the same number, someone is copying a reference figure rather than running the test.

Missing method references are also a flag. A COA should state the test method for each parameter — not just the result. “Particle size: 180 nm” tells us nothing about whether that was DLS, laser diffraction, or NTA. These methods give different numbers on the same sample.

On the interaction side: suppliers who resist third-party testing of their material, suppliers who cannot provide the manufacturing date (as opposed to the expiry date), and suppliers who offer discounts for reduced testing are all patterns we treat as disqualifying. The discount offer in particular — “we can reduce the price if you don’t require the full COA package” — is something we’ve encountered from three different suppliers over the past two years. We decline and document it.

One more thing that comes up less often but matters: formulation transparency. For proprietary encapsulated actives, suppliers won’t always disclose full shell composition. That’s understandable commercially. But we require enough information to assess regulatory compliance — specifically, whether any shell component appears on the EU Annex II prohibited list or falls within nano-material notification requirements under SCCS Scientific Opinion guidance. If a supplier cannot provide that minimum regulatory disclosure, we can’t use the material in EU-destined formulations. It’s that simple.

Clinical Grounding — Why EE% Thresholds Are Set Where They Are #

The 85% EE threshold for lipid-based systems is not arbitrary. It’s grounded in the performance data. A 2019 double-blind, vehicle-controlled split-face study (n=46, 12 weeks) comparing a liposome-encapsulated retinol formulation at 85% EE versus an equivalent formula using 72% EE material found a 34% greater reduction in fine line depth scores (modified Fitzpatrick wrinkle scale) in the 85% EE arm at week 12. The lower EE arm showed meaningful improvement versus vehicle, but the high-EE arm was statistically and clinically distinct. The proposed mechanism is lower free retinol content at application, reducing competing oxidative degradation pathways in the stratum corneum before the active reaches the viable epidermis.

We cite this internally when brands push back on material cost. Higher EE material costs more. The data makes the case for why it matters — not just for consumer outcome, but for stability in the finished formula. Free retinol degrades faster, drives formula yellowing, and increases the probability of irritation complaints. Our anti-aging category work with retinol and peptide encapsulates consistently shows that the biggest predictor of 12-month real-time stability success is the EE% of the incoming material, not the formula system around it.

We’re still not fully convinced the clinical evidence generalises cleanly to every encapsulation system. The 2019 data was specific to phospholipid liposomal retinol. For NLC or polymer microsphere systems, the release kinetics and therefore the active fraction available at the skin surface are different. Our dataset on those comparisons is growing but not yet definitive.

Formulation Notes for Brand Partners #

When you brief us on an encapsulated active, the first questions we ask are: what market is this going to, what’s the format, and what’s the on-pack claims story? Those three answers change everything about the incoming qualification burden.

A retinol serum for the EU requires us to track nano-material notification status for any particle under 100 nm — that’s a supplier disclosure requirement before we even start. A vitamin C encapsulate for a US clean beauty brand may face no regulatory nano threshold, but the retailer’s ingredient policy might restrict certain shell materials (polyacrylate-based systems, for example, appear on several clean beauty avoid lists regardless of safety data).

The most common brief mistake we see: brands request a specific supplier’s encapsulated active by trade name without providing an existing COA. We’ve had briefs where the trade name turns out to correspond to three different supplier variants with different EE% specifications. We push back and require a current COA before pricing or sampling begins — not to create delay, but because formulating against the wrong EE% wastes a full stability cycle.

Lab samples: 2–3 weeks from confirmed raw material approval. Accelerated stability: 4–8 weeks at 40°C/75% RH. Twenty-four-month real-time stability is initiated concurrently. The accelerated data informs early go/no-go; real-time data supports the final shelf-life claim.

Frequently Asked Questions #

Can we use a supplier’s COA without running our own incoming tests?
A: We run at minimum a particle size check and free-active assay on every incoming lot regardless of supplier COA, because COA data represents the supplier’s QC, not ours. For high-risk actives like retinol or ascorbic acid derivatives, we add peroxide value and zeta potential to every lot check.

What regulations actually govern encapsulated cosmetic ingredients in the EU?
A: The primary framework is EU Cosmetics Regulation 1223/2009, which requires that nano-form ingredients — particles below 100 nm — be notified to the Commission six months before market placement. Shell composition also has to be assessed against Annex II and III restricted/prohibited lists. SCCS Scientific Opinion guidance on nanomaterials has shifted more than once in recent years, so if you’re targeting EU with a nano-range encapsulate, the regulatory landscape today may not be the same in 18 months.

What’s the most common stability failure you see with incoming encapsulated materials?
A: Shell oxidation is the failure mode we catch most often — specifically, lipid-based systems where peroxide value at incoming is borderline (3.5–4.9 meq/kg) and the material has consumed more than 40% of its shelf life before we receive it. By week 8 of accelerated stability, active assay is significantly below target. We’ve had three separate projects in the past two years where this was the root cause of a stability failure that initially looked like a formula issue.

What’s your MOQ and lead time for formulas using encapsulated actives?
A: MOQ for finished product is typically 500 kg per SKU for standard formats. Lead time from confirmed raw material approval to first lab samples is 2–3 weeks; pilot batch for stability initiation is 6–8 weeks. If the encapsulated active requires third-party sourcing with a long lead time, that can extend the timeline by 3–4 weeks — something we map out in the project kickoff.

Should we disclose encapsulation on the product label, and does it affect INCI naming?
A: It depends on the system. Liposome-encapsulated actives are typically listed under the active’s INCI name with no separate disclosure required. Polymer microsphere systems may add a polymer carrier to the INCI list — for PLGA systems, that would appear as “polylactic-co-glycolic acid” or similar. Where it gets complicated is nano-range materials in the EU: EU Cosmetics Regulation 1223/2009 requires nano ingredients to be listed with “[nano]” in brackets after the INCI name. Brands often don’t factor this into their label artwork timeline, and we flag it early in every EU project.

---

Have a product concept in mind? Contact our formulation team to request a complimentary brief review.